Submission of Annual Report for the FY 2024-25
Awaiting price reaction for this filing.
Sangam Health Care Products Ltd submitted its 31st Annual Report for FY 2024-25 to BSE on September 5, 2025, along with the notice of the 31st Annual General Meeting scheduled for September 30, 2025. For FY24-25, the company reported total income of Rs. 1,248.07 lakhs (up from Rs. 1,210.84 lakhs in FY23-24) and a profit of Rs. 44.97 lakhs (up from Rs. 41.84 lakhs). Turnover stood at Rs. 1,245.96 lakhs with profit before tax of Rs. 25.47 lakhs. No dividend was recommended. Key business items include the re-appointment of M/s M.M. Reddy & Co. as statutory auditors for a second 5-year term (till 2030 AGM) and the appointment of M/s Chakravarthy & Associates as Secretarial Auditor for FY 2025-26 to FY 2029-30.
Significant positive development: the Securities Appellate Tribunal Mumbai ordered restoration of the company's BSE listing on April 17, 2025 after it was delisted in November 2024, which is a major relief for shareholders. Modest financial growth (revenue +3%, profit +7%) and zero dividend reflect a small-cap company prioritizing growth over payouts.